Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis.
about
Targeted therapies to improve CFTR function in cystic fibrosisA synthetic chloride channel restores chloride conductance in human cystic fibrosis epithelial cellsMyotonia congenita mutation enhances the degradation of human CLC-1 chloride channelsIon channel associated diseases: overview of molecular mechanismsA novel epileptic encephalopathy mutation in KCNB1 disrupts Kv2.1 ion selectivity, expression, and localization.Local modulation of cystic fibrosis conductance regulator: cytoskeleton and compartmentalized cAMP signalling.CFTR: folding, misfolding and correcting the ΔF508 conformational defect.Nonequilibrium gating of CFTR on an equilibrium theme.CFTR potentiators partially restore channel function to A561E-CFTR, a cystic fibrosis mutant with a similar mechanism of dysfunction as F508del-CFTRTranscriptomic profile of cystic fibrosis patients identifies type I interferon response and ribosomal stalk proteins as potential modifiers of disease severityFixing cystic fibrosis by correcting CFTR domain assembly.Channelopathies and drug discovery in the postgenomic era.Partial rescue of F508del-CFTR channel gating with modest improvement of protein processing, but not stability by a dual-acting small molecule.Cerebral artery myogenic reactivity: The next frontier in developing effective interventions for subarachnoid hemorrhage.Repairing folding-defective α-sarcoglycan mutants by CFTR correctors, a potential therapy for Limb Girdle Muscular Dystrophy 2D.Thymosin α-1 does not correct F508del-CFTR in cystic fibrosis airway epithelia.Structural mechanisms of CFTR function and dysfunction.The EGFR-ADAM17 Axis in Chronic Obstructive Pulmonary Disease and Cystic Fibrosis Lung Pathology.Impact of the cystic fibrosis mutation F508del-CFTR on renal cyst formation and growth
P2860
Q26781441-96ADACAD-BE21-425A-A6C6-612D39FBC7F9Q27305063-2F2AFF1B-D9C7-4396-8500-4BB7C7868AC8Q28486132-C302644F-0E3C-458F-A2F7-D672EBADCF35Q34311621-4BC745C5-099E-44EE-877A-9D26E6AA1DEFQ36210361-1329B86C-9891-46CF-AE5C-6410EBDA6A79Q36783966-075B3DF3-967F-4681-9F64-96C91998C0C2Q36814102-47B5DCFA-FCCD-466E-B364-E738D568CC2EQ37061709-B4814ED3-473B-4375-AD15-C65ECA990ABFQ38987933-44A50179-321A-45A7-9FCD-70CE90E12C51Q41533194-310BECDB-E5E2-43FB-BBC7-5096991FE536Q42426222-616ABD2C-C121-41BC-874D-889B3447E654Q42554247-EF1F7A45-6034-4AF5-9706-50E58394AB10Q47214928-AC7FCAD1-9084-40C8-9720-330789E87B14Q47285240-E5F980C3-A06D-4572-A53C-62360D463432Q48530686-72A70236-8020-458D-A35C-1615B2CA43A1Q50130517-613CF5BA-96C8-4B68-A075-47E994CE9119Q52629670-85A5D170-BEDB-4FC1-9589-CBB14603C098Q55177212-6F5D607D-C82E-47E0-98FA-B8A2DEDB8657Q57762189-E0D7B04A-B95D-422E-927F-84CDBBE9028A
P2860
Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis.
@en
Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis.
@nl
type
label
Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis.
@en
Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis.
@nl
prefLabel
Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis.
@en
Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis.
@nl
P2093
P2860
P356
P1476
Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis.
@en
P2093
David N Sheppard
Hong-yu Li
Zhi-wei Cai
P2860
P2888
P304
P356
10.1038/APS.2011.71
P577
2011-06-01T00:00:00Z